{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:03:48Z","timestamp":1788458628293,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bbalip.2020.158733","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T11:00:47Z","timestamp":1588330847000},"page":"158733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis"],"prefix":"10.1016","volume":"1865","author":[{"given":"Adriana","family":"Carino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Biagioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Marchian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Fiorucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bordoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Roselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Di Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva","family":"Morretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zampella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fiorucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5418","key":"10.1016\/j.bbalip.2020.158733_bb0005","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bbalip.2020.158733_bb0010","doi-asserted-by":"crossref","first-page":"29320","DOI":"10.1038\/srep29320","article-title":"Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands","volume":"6","author":"Finamore","year":"2016","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.bbalip.2020.158733_bb0015","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbalip.2020.158733_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The pharmacology of bile acids and their receptors","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbalip.2020.158733_bb0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bbalip.2020.158733_bb0030","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1074\/jbc.M411451200","article-title":"Nrf2 transcriptionally activates the mafG gene through an antioxidant response element","volume":"280","author":"Katsuoka","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bbalip.2020.158733_bb0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1053\/j.gastro.2018.04.032","article-title":"Mechanisms of MAFG dysregulation in cholestatic liver injury and development of liver cancer","volume":"155","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.bbalip.2020.158733_bb0040","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/hep.22908","article-title":"Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications","volume":"49","author":"Yang","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.bbalip.2020.158733_bb0045","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.23471","article-title":"Induction of avian musculoaponeurotic fibrosarcoma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice","volume":"51","author":"Yang","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bbalip.2020.158733_bb0050","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.28541","article-title":"Deregulated methionine adenosyltransferase \u03b11, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans(\u2021)","volume":"64","author":"Yang","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bbalip.2020.158733_bb0055","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cmet.2015.01.007","article-title":"MAFG is a transcriptional repressor of bile acid synthesis and metabolism","volume":"21","author":"de Aguiar Vallim","year":"2015","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.bbalip.2020.158733_bb0060","first-page":"305","article-title":"Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat","volume":"65","author":"Kountouras","year":"1984","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.bbalip.2020.158733_bb0065","doi-asserted-by":"crossref","first-page":"19008","DOI":"10.1038\/srep19008","article-title":"Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists","volume":"6","author":"Sepe","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bbalip.2020.158733_bb0070","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1021\/acsmedchemlett.8b00423","article-title":"Novel isoxazole derivatives with potent FXR agonistic activity prevent acetaminophen-induced liver injury","volume":"10","author":"Sepe","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"20","key":"10.1016\/j.bbalip.2020.158733_bb0075","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"J. Med. Chem."},{"issue":"9\u201310","key":"10.1016\/j.bbalip.2020.158733_bb0080","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0278-6915(99)00082-4","article-title":"Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes","volume":"37","author":"Fahey","year":"1999","journal-title":"Food Chem. Toxicol."},{"issue":"16","key":"10.1016\/j.bbalip.2020.158733_bb0085","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1021\/jm0002127","article-title":"Identification of a chemical tool for the orphan nuclear receptor FXR","volume":"43","author":"Maloney","year":"2000","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bbalip.2020.158733_bb0090","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"112","author":"Liu","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bbalip.2020.158733_bb0095","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acsmedchemlett.8b00534","article-title":"Investigation around the oxadiazole core in the discovery of a new chemotype of potent and selective FXR antagonists","volume":"10","author":"Festa","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bbalip.2020.158733_bb0100","doi-asserted-by":"crossref","first-page":"7857186","DOI":"10.1155\/2016\/7857186","article-title":"Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician\u2019s expectation be matched by the reality?","volume":"2016","author":"Houghton","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.bbalip.2020.158733_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Liver, EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"E.A.f.t.S.o.t.L.E.a. easloffice@easloffice.eu, E.A.f.t.S.o.t","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbalip.2020.158733_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic acid: an update of its pharmacological activities in liver disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbalip.2020.158733_bb0115","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.105.093765","article-title":"Induction of hepatic transporters multidrug resistance-associated proteins (Mrp) 3 and 4 by clofibrate is regulated by peroxisome proliferator-activated receptor alpha","volume":"317","author":"Moffit","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bbalip.2020.158733_bb0120","doi-asserted-by":"crossref","first-page":"G126","DOI":"10.1152\/ajpgi.00522.2010","article-title":"Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression","volume":"299","author":"Xu","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"21","key":"10.1016\/j.bbalip.2020.158733_bb0125","doi-asserted-by":"crossref","first-page":"22250","DOI":"10.1074\/jbc.M314111200","article-title":"Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice","volume":"279","author":"Assem","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2020.158733_bb0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.biochem.71.102301.093055","article-title":"Mammalian ABC transporters in health and disease","volume":"71","author":"Borst","year":"2002","journal-title":"Annu. Rev. Biochem."},{"issue":"2","key":"10.1016\/j.bbalip.2020.158733_bb0135","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","author":"Trauner","year":"2003","journal-title":"Physiol. Rev."},{"issue":"30","key":"10.1016\/j.bbalip.2020.158733_bb0140","doi-asserted-by":"crossref","first-page":"11323","DOI":"10.1073\/pnas.0604772103","article-title":"Benefit of farnesoid X receptor inhibition in obstructive cholestasis","volume":"103","author":"Stedman","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbalip.2020.158733_bb0145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/toxsci\/kfp094","article-title":"Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice","volume":"110","author":"Cui","year":"2009","journal-title":"Toxicol. Sci."},{"issue":"1","key":"10.1016\/j.bbalip.2020.158733_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030443","article-title":"Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis","volume":"7","author":"Renga","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bbalip.2020.158733_bb0155","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.104.079665","article-title":"Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis","volume":"313","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbalip.2020.158733_bb0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2019_237","article-title":"Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists, and antagonists","volume":"256","author":"De Marino","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbalip.2020.158733_bb0165","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1053\/j.gastro.2015.10.014","article-title":"MafG, a novel target of FXR that regulates bile acid homeostasis","volume":"149","author":"Yang","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbalip.2020.158733_bb0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.fct.2018.07.024","article-title":"The role of nuclear factor erythroid 2-related factor 2 in hepatoprotective activity of natural products: a review","volume":"120","author":"Iranshahy","year":"2018","journal-title":"Food Chem. Toxicol."},{"issue":"12","key":"10.1016\/j.bbalip.2020.158733_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122772","article-title":"Nrf2, the master regulator of anti-oxidative responses","volume":"18","author":"Vomund","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbalip.2020.158733_bb0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.alcohol.2005.03.011","article-title":"Role of methionine adenosyltransferase and S-adenosylmethionine in alcohol-associated liver cancer","volume":"35","author":"Lu","year":"2005","journal-title":"Alcohol"},{"issue":"2","key":"10.1016\/j.bbalip.2020.158733_bb0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.livres.2017.07.002","article-title":"Methionine adenosyltransferases in liver health and diseases","volume":"1","author":"Ramani","year":"2017","journal-title":"Liver Res."},{"issue":"3","key":"10.1016\/j.bbalip.2020.158733_bb0190","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/0115426506021003255","article-title":"The use of selected nutrition supplements and complementary and alternative medicine in liver disease","volume":"21","author":"Hanje","year":"2006","journal-title":"Nutr. Clin. Pract."},{"issue":"5","key":"10.1016\/j.bbalip.2020.158733_bb0195","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00726-019-02716-3","article-title":"Comparison between the effects of selenomethionine and S-adenosylmethionine in preventing cholestasis-induced rat liver damage","volume":"51","author":"Brza\u010dki","year":"2019","journal-title":"Amino Acids"},{"issue":"1","key":"10.1016\/j.bbalip.2020.158733_bb0200","doi-asserted-by":"crossref","first-page":"14130","DOI":"10.1038\/s41598-017-14520-8","article-title":"Sulforaphane reactivates cellular antioxidant defense by inducing Nrf2\/ARE\/Prdx6 activity during aging and oxidative stress","volume":"7","author":"Kubo","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bbalip.2020.158733_bb0205","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.etp.2010.11.005","article-title":"Protective effect of sulforaphane against oxidative stress: recent advances","volume":"64","author":"Guerrero-Beltr\u00e1n","year":"2012","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.bbalip.2020.158733_bb0210","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.abb.2016.08.005","article-title":"Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants","volume":"617","author":"Dinkova-Kostova","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.bbalip.2020.158733_bb0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00204-011-0674-5","article-title":"The cytoprotective role of the Keap1-Nrf2 pathway","volume":"85","author":"Baird","year":"2011","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bbalip.2020.158733_bb0220","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/164_2019_226","article-title":"Chenodeoxycholic acid: an update on its therapeutic applications","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbalip.2020.158733_bb0225","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_232","article-title":"Nonsteroidal FXR ligands: current status and clinical applications","volume":"256","author":"Gege","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"issue":"15","key":"10.1016\/j.bbalip.2020.158733_bb0230","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.bmcl.2016.05.070","article-title":"Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: understanding and improving key determinants of pharmacological properties","volume":"26","author":"Kinzel","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bbalip.2020.158733_bb0235","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cts.12421","article-title":"Modeling and experimental studies of obeticholic acid exposure and the impact of cirrhosis stage","volume":"9","author":"Edwards","year":"2016","journal-title":"Clin. Transl. Sci."},{"issue":"6","key":"10.1016\/j.bbalip.2020.158733_bb0240","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/me.2010-0512","article-title":"Bile acid receptor agonist GW4064 regulates PPAR\u03b3 coactivator-1\u03b1 expression through estrogen receptor-related receptor \u03b1","volume":"25","author":"Dwivedi","year":"2011","journal-title":"Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.bbalip.2020.158733_bb0245","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.bbalip.2020.158733_bb0250","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1038\/s41467-019-10853-2","article-title":"Molecular tuning of farnesoid X receptor partial agonism","volume":"10","author":"Merk","year":"2019","journal-title":"Nat. Commun."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198120301256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1388198120301256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:05:59Z","timestamp":1761386759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1388198120301256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1388198120301256"],"URL":"https:\/\/doi.org\/10.1016\/j.bbalip.2020.158733","relation":{},"ISSN":["1388-1981"],"issn-type":[{"value":"1388-1981","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbalip.2020.158733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"158733"}}